SIC
LGND icon

SJS Investment Consulting’s Ligand Pharmaceuticals LGND Stock Holding History

SJS Investment Consulting’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.64K Buy
21
+20
+2,000% +$4.71K ﹤0.01% 1265
2026
Q1 		$200 Buy
+1
New +$198 ﹤0.01% 1986
2023
Q4 		– Sell
-2
Closed -$120 – 1632
2023
Q3 		$120 Hold
2
– – ﹤0.01% 1521
2023
Q2 		$145 Hold
2
– – ﹤0.01% 1465
2023
Q1 		$148 Sell
2
-1
-33% -$71 ﹤0.01% 1410
2022
Q4 		$200 Buy
3
+1
+50% +$65 ﹤0.01% 1412
2022
Q3 		$0 Buy
+2
New +$118 ﹤0.01% 1313

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

SJS Investment Consulting's LGND Position: Q2 2026 in Review

SJS Investment Consulting increased its Ligand Pharmaceuticals (LGND) stake by 2,000% in Q2 2026, buying an estimated $4.71K and bringing the position to 21 shares worth $6.64K. The position accounts for ﹤0.01% of the portfolio, ranked #1265.

SJS Investment Consulting first reported a position in LGND in Q3 2022 and has held it in 7 quarters since. 121 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • SJS Investment Consulting held 21 shares of Ligand Pharmaceuticals worth $6.64K as of Q2 2026.
  • SJS Investment Consulting bought 20 Ligand Pharmaceuticals shares in Q2 2026, an estimated $4.71K.
  • Ligand Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1265 holding.
  • SJS Investment Consulting first reported a position in Ligand Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
  • 121 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.